Molecular Partners AG (MOLN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Molecular Partners AG (MOLN) closed at USD 3.65 on 2026-10-14, a change of -2.7 % over the past year, with a market capitalization of USD 135.35M.

Molecular Partners AG recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Molecular Partners AG key figures

Previous close

USD 3.65 (2026-10-14)

1-year change

-2.7 %

Market cap

USD 135.35M

Enterprise value

USD 74.93M

P/E ratio (trailing)

-2.08

P/E ratio (forward)

-21.61

EPS (trailing)

-1.70

EPS (forward)

-0.16

PEG ratio

n/a

Price to book

1.92

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.22

Employees

134

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Molecular Partners AG and compare it with other stocks.